Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Enfuvirtide
The first HIV entry inhibitor — a 36-amino-acid peptide that blocks viral fusion.
Icatibant
A synthetic decapeptide that blocks bradykinin B2 receptors, approved for acute attacks of hereditary angioedema in adults.
How far human research has progressed
Enfuvirtide
Approved antiretroviral, now largely historical in practiceIcatibant
Approved rare-disease medicineClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Enfuvirtide
Not separately assessed; see the full profile.Icatibant
Not separately assessed; see the full profile.Human research context
Enfuvirtide
Approved antiretroviral, now largely historical in practiceIcatibant
Approved rare-disease medicineHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Enfuvirtide
Icatibant
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Enfuvirtide
Icatibant
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Enfuvirtide
Icatibant
Regulatory status (legal position, not proof it works)
Enfuvirtide
Named regulators: FDA (US)
FDA-approved (Fuzeon) in combination with other antiretrovirals for treatment-experienced patients with HIV-1 with evidence of ongoing viral replication. Approval is specific to that role in combination therapy.
Icatibant
Named regulators: FDA (US)
FDA-approved (Firazyr) for treatment of acute attacks of hereditary angioedema in adults 18 years and older, given by subcutaneous injection.
Common claims
Enfuvirtide
- · Reduces viral load in treatment-experienced HIV-1 patients as part of combination therapy
Icatibant
- · Treats acute hereditary angioedema attacks
How settled our evidence rating is
Enfuvirtide
Icatibant
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Enfuvirtide
No established human cancer signal within approved use.Icatibant
No established human cancer signal within approved use.What this adds up to, in plain English
Enfuvirtide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Icatibant
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation